no official package insert Clinical trial status / No completed Phase III trials in humans for TB-500 specifically Bulk drug substance status / Subject to ongoing FDA review for compounding eligibility DEA scheduling / TB-500 is not a controlled substance Key safety concern / No large-scale human safety data from randomized controlled trials Regulatory trend / FDA has increased scrutiny of peptide compounding since 2023 Parent molecule research / Thymosin beta-4 studied in wound healing and cardiac repair preclinical models TB-500 Has No FDA Approval TB-500 has never been submitted to or approved by the FDA through a New Drug Application (NDA) or Biologics License Application (BLA)
While Dihexa is generally well-tolerated, even the safest compounds can sometimes produce mild side effects
A 2020 human clinical trial found that cosmetics containing Artemisia Annua Extract increased stratum corneum hydration and reduced transepidermal water loss while also calming redness and inflammation over four weeks of use
How BPC-157 Is Applied BPC-157 can be administered through subcutaneous injections or orally, although the former is considered more effective
CLOCK/ and BMAL1/ mice exhibit disorders of glucose metabolism and circadian changes in circulating glucose and triglycerides, which lead to obesity, hyperlipidemia, and diabetes (Rudic et al., 2004
20mg vial add 5.0mL (4mg/mL)